Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Nagao, Hirofumi ^a   Kashine, Susumu ^b   Nishizawa, Hitoshi ^a   Okada, Takuya ^c   Kimura, Takekazu ^a   Hirata, Ayumu ^a   Fukuda, Shiro ^a   Kozawa, Junji ^a   Maeda, Norikazu ^a   Kitamura, Tetsuhiro ^a   Yasuda, Tetsuyuki ^a   Okita, Kohei ^a   Hibuse, Toshiyuki ^b   Tsugawa, Mamiko ^c   Imagawa, Akihisa ^a   Funahashi, Tohru ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Suita Municipal Hospital   (Japan)

^c IKEDA MUNICIPAL HOSPITAL   (Japan)

Author keywords

Abdominal obesity; Body mass index; Cardiovascular disease; Type 2 diabetes; Visceral fat accumulation; Waist circumference

Indexed keywords

ABDOMINAL OBESITY; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIABETIC PATIENT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INTRAABDOMINAL FAT; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; WAIST CIRCUMFERENCE; ABDOMINAL FAT; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; COMORBIDITY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE COURSE; EPIDEMIOLOGY; ETHNOLOGY; HOSPITALIZATION; JAPAN; MIDDLE AGED; OBESITY; OBESITY, ABDOMINAL; PATHOPHYSIOLOGY; RISK FACTOR; TIME; WEIGHT GAIN; YOUNG ADULT;

ABDOMINAL FAT; ADIPOSITY; ADULT; AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; JAPAN; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; PREVALENCE; RISK FACTORS; TIME FACTORS; WAIST CIRCUMFERENCE; WEIGHT GAIN; YOUNG ADULT;

EID: 84879059402     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-88     Document Type: Article

References (48)

1. World Health Organization Obesity and overweight; WHO Fact Sheet No311 2013, http://www.who.int/mediacentre/factsheets/fs311/en/index.html, 3684724, 23785677, World Health Organization.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4-14. 10.1016/j.diabres.2009.10.007, 19896746.
3. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006, 368:1681-1688. 10.1016/S0140-6736(06)69703-1, 17098087.
4. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia. epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-2140. 10.1001/jama.2009.726, 19470990.
5. Fujimoto WY. Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups. Diabet Med 1996, 13:S7-S10.
6. Fujimoto WY, Akanuma Y, Kanazawa Y, Mashiko S, Leonetti D, Wahl P. Plasma insulin levels in Japanese and Japanese-American men with type 2 diabetes may be related to the occurrence of cardiovascular disease. Diabetes Res Clin Pract 1989, 6:121-127. 10.1016/0168-8227(89)90116-2, 2647443.
7. Huxley R, James WP, Barzi F, Patel JV, Lear SA, Suriyawongpaisal P, Janus E, Caterson I, Zimmet P, Prabhakaran D, Reddy S, Woodward M. Obesity in Asia Collaboration. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev 2008, 9:53-61. 10.1111/j.1467-789X.2007.00439.x, 18307700.
8. Nagaya T, Yoshida H, Takahashi H, Kawai M. Increases in body mass index, even within non-obese levels, raise the risk for Type 2 diabetes mellitus: a follow-up study in a Japanese population. Diabet Med 2005, 22:1107-1111. 10.1111/j.1464-5491.2005.01602.x, 16026381.
9. Oh SW, Shin SA, Yun YH, Yoo T, Huh BY. Cut-off point of BMI and obesity-related comorbidities and mortality in middle-aged Koreans. Obes Res 2004, 12:2031-2040. 10.1038/oby.2004.254, 15687405.
10. Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM, de Lemos JA. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring) 2012, Epub ahead of print.
11. Iwahashi H, Okauchi Y, Ryo M, Noguchi M, Morita S, Kishida K, Okita K, Ohira T, Funahashi T, Nakamura T, Imagawa A, Shimomura I. Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients. J Diabetes Invest 2012, 3:271-275.
12. Okauchi Y, Nishizawa H, Funahashi T, Ogawa T, Noguchi M, Ryo M, Kihara S, Iwahashi H, Yamagata K, Nakamura T, Shimomura I, Matsuzawa Y. Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men. Diabetes Care 2007, 30:2392-2394. 10.2337/dc07-0218, 17563343.
13. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982, 54:254-260. 10.1210/jcem-54-2-254, 7033275.
14. Nakamura T, Tokunaga K, Shimomura I, Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, Kotani K, Islam AH, Keno Y, Kobatake T, Nagai Y, Fujioka S, Tarui S, Matsuzawa Y. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994, 107:239-246. 10.1016/0021-9150(94)90025-6, 7980698.
15. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996, 2:800-803. 10.1038/nm0796-800, 8673927.
16. Hotmisligli GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995, 95:2409-2415. 10.1172/JCI117936, 295872, 7738205.
17. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360:57-58. 10.1016/S0140-6736(02)09335-2, 12114044.
18. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004, 68:975-981. 10.1253/circj.68.975, 15502375.
19. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Adiponectin in essential hypertension. J Nephrol 2002, 15:507-511.
20. Mohammadreza B, Farzad H, Davoud K, Fereidoun Prof AF. Prognostic significance of the complex " Visceral Adiposity Index" vs. simple anthropometric measures: Tehran lipid and glucose study. Cardiovasc Diabetol 2012, 11-20.
21. Hiuge-Shimizu A, Kishida K, Funahashi T, Ishizaka Y, Oka R, Okada M, Suzuki S, Takaya N, Nakagawa T, Fukui T, Fukuda H, Watanabe N, Yoshizumi T, Nakamura T, Matsuzawa Y, Yamakado M, Shimomura I. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). Ann Med 2012, 44:82-92. 10.3109/07853890.2010.526138, 20964583.
22. New criteria for 'obesity disease' in Japan. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity New criteria for 'obesity disease' in Japan. Examination Committee of Criteria for 'Obesity Disease' in Japan. Circ J 2002, 66:987-992. 10.1253/circj.66.987, 12419927, New criteria for 'obesity disease' in Japan. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity.
23. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M. Metabolic syndrome. J Atheroscler Thromb 2008, 15:1-5. 10.5551/jat.E580, 18319538.
24. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H. International clinical harmonization of glycated hemoglobin in Japan : From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012, 3:39-40.
25. Yki-Järvinen H, Esko N, Eero H, Marja-Riitta T. Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am J Med 1988, 84:185-92. 10.1016/0002-9343(88)90412-3, 3044067.
26. Hiatt WR. Medical Treatment of Peripheral Arterial Disease and Claudication. N Engl J Med 2001, 344:1608-1621. 10.1056/NEJM200105243442108, 11372014.
27. Mohler ER. Peripheral arterial disease: identification and implications. Arch Intern Med 2003, 163:2306-2314. 10.1001/archinte.163.19.2306, 14581250.
28. Smith U, Hammersten J, Björntorp P, Kral JG. Regional differences and effect of weight reduction on human fat cell metabolism. Eur J Clin Invest 1979, 9:327-332. 10.1111/j.1365-2362.1979.tb00892.x, 118025.
29. Mittelman SD, Van Citters GW, Kirkman EL, Bergman RN. Extreme insulin resistance of the central adipose depot in vivo. Diabetes 2002, 51:755-761. 10.2337/diabetes.51.3.755, 11872676.
30. Londos C, Brasaemle DL, Schultz CJ, Adler-Wailes DC, Levin DM, Kimmel AR, Rondinone CM. On the control of lipolysis in adipocytes. Ann N Y Acad Sci 1999, 892:155-168. 10.1111/j.1749-6632.1999.tb07794.x, 10842661.
31. Kuriyama H, Yamashita S, Shimomura I, Funahashi T, Ishigami M, Aragane K, Miyaoka K, Nakamura T, Takemura K, Man Z, Toide K, Nakayama N, Fukuda Y, Lin MC, Wetterau JR, Matsuzawa Y. Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology 1998, 27:557-562. 10.1002/hep.510270233, 9462657.
32. White DA, Bennett AJ, Billett MA, Salter AM. The assembly of triacylglycerol-rich lipoproteins: an essential role for the microsomal triacylglycerol transfer protein. Br J Nutr 1998, 80:219-229.
33. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med 2001, 11:170-176. 10.1016/S1050-1738(01)00084-6, 11597827.
34. Kuriyama H, Shimomura I, Kishida K, Kondo H, Furuyama N, Nishizawa H, Maeda N, Matsuda M, Nagaretani H, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y. Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. Diabetes 2002, 51:2915-2921. 10.2337/diabetes.51.10.2915, 12351427.
35. Maeda N, Funahashi T, Shimomura I. Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9. Nat Clin Pract Endocrinol Metab 2008, 4:627-34.
36. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001, 23:531-543.
37. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011, 18:629-639. 10.5551/jat.7922, 21737960.
38. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099. 10.2337/diabetes.50.9.2094, 11522676.
39. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006, 70:1717-1724. 10.1038/sj.ki.5001810, 16985520.
40. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D, Matas Z, Hibuse T, Fujita K, Nishizawa H, Adler Y, Motro M, Kihara S, Shimomura I, Behar S, Funahashi T. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007, 27:635-641. 10.1161/01.ATV.0000256469.06782.d5, 17194889.
41. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol 2011, 10:109. 10.1186/1475-2840-10-109, 3260096, 22132774.
42. Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol 2012, 11:107. 10.1186/1475-2840-11-107, 3459720, 22973968.
43. Yoshida Y, Hagura R, Hara Y, Sugasawa G, Akanuma Y. Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2001, 51:195-203. 10.1016/S0168-8227(00)00212-6, 11269892.
44. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR, UKPDS 50 risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001, 44:156-163. 10.1007/s001250051594, 11270671, UKPDS 50.
45. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
46. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
47. Lee IT, Chiu YF, Hwu CM, He CT, Chiang FT, Lin YC, Assimes T, Curb JD, Sheu WH. Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study. Cardiovasc Diabetol 2012, 11:43. 10.1186/1475-2840-11-43, 3476431, 22537054.
48. Nooyens AC, van Duijnhoven FJ, Verschuren WM, Boer JM, van der A DL All-cause mortality risk of metabolically healthy abdominal obese individuals: The EPIC-MORGEN study. Obesity (Silver Spring) 2013, Epub ahead of print, van der A DL.